Pediatric Vitiligo Study: Ruxolitinib Cream Phase 3 Trial

This Phase 3 study is testing a cream called ruxolitinib in children ages 2 to under 12 who have nonsegmental vitiligo, a skin condition that causes white patches.

The study lasts about 1 year (52 weeks) and has two parts:

1. First 24 weeks: children will be randomly assigned to receive either ruxolitinib cream or a placebo cream (does not contain medication).
2. Next 28 weeks: all participants may receive ruxolitinib cream.

The main goal is to see how many children have at least 75% improvement in facial repigmentation by Week 24.

Ruxolitinib is a JAK inhibitor that has already shown positive results in teens and adults with vitiligo. This study will help determine if it is safe and effective for younger children.

In order to participate your child must meet the following criteria:

• Are 2–11 years of age with nonsegmental vitiligo on the face and body.
• Have vitiligo that covers no more than 10% of the body.
• Have some areas of vitiligo on the face that have pigmented hair present.
• Are willing to pause all other vitiligo treatments during the study.

Your child will be excluded from the study if any of the following criteria apply:

• Have segmental vitiligo or another skin condition that causes depigmentation.
• Have previously used depigmentation treatments (such as monobenzone).
• Are currently or have previously used JAK inhibitor medications (oral or topical).
• Have a medical condition that would make it unsafe to participate or interfere with study visits.

This is a partial list of eligibility requirements. To inquire about your child's eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.